Tribological behavior and in vitro biocompatibility of powder metallurgical Ti-15Mo/HA composite for bone repair.

Ti-15Mo/HA composite was prepared by powder metallurgy, and the influence of Hydroxyapatite (HA) on the microstructure, tribological behavior and in vitro biocompatibility was studied by comparison with TC4. The results show that the Ti-15Mo/HA composite consists of increased α-Ti, decreased ß-Ti and a variety of ceramic phases (CaTiO3, Ca3(PO4)2, CaO, etc.) with the increase of HA content. The friction coefficient and wear rate of Ti-15Mo/HA composite is apparently lower than those of TC4 due to solid solution strengthening of Mo in Ti and dispersion strengthening of ceramic phases. Ti-15Mo/5HA displays more excellent wear resistance than the other composite. TC4 alloy is dominated by adhesive wear, however, Ti-15Mo alloy is a combination of adhesive wear and abrasive wear. Ti-15Mo/HA composite is mainly subjected to abrasive wear, together with adhesive wear. The viability and the number of mouse osteoblasts in Ti-15Mo/5HA extract are higher than that of Ti-15Mo. The morphology of the osteoblasts is clear and full, and the growth and proliferation are satisfactory with the increased cell pseudopodia with the culture time. The Ti-15Mo/HA composite displays good wear resistance and biocompatibility, and accordingly has a potential application in bone repair materials.

Chemotherapy for thymic carcinoma and advanced thymoma in adults.

BACKGROUND: Thymic carcinoma or advanced thymoma is a rare cancer of the thymus gland that tends to be aggressive and infiltrate neighbouring organs, making total resection very difficult. Induction or adjuvant chemotherapy, or both, are often used in a multimodality approach to treat people affected by this condition, but the effectiveness of chemotherapy for thymic carcinoma or advanced thymoma remains uncertain. OBJECTIVES: To assess the role of chemotherapy in adults with thymic carcinoma or advanced thymoma. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2012, Issue 7), MEDLINE (accessed via Ovid from 1966 to July 2012), EMBASE (accessed via Ovid, from 1980 to July 2012), Latin American and Caribbean Literature on Health Sciences (LILACS), the Chinese Biological Medicine Database (CBM, 1978 to July 2012), China National Knowledge Infrastructure (CNKI, 1980 to July 2012) and the Chinese scientific periodical database VIP Information (VIP, 1989 to July 2012). There was no language restriction in searching for studies. SELECTION CRITERIA: We planned to include randomised controlled trials (RCTs) of  trials using chemotherapy (either single-agent or combination chemotherapy plus surgery, radiotherapy or not) for thymic carcinoma and/or advanced thymoma. We planned to include all adults (aged 18 years and over) diagnosed with thymic carcinoma and/or with Masaoka stage III or IV thymic tumours. The intended primary outcomes were overall survival (OS) and progression-free survival (PFS). DATA COLLECTION AND ANALYSIS: Two review authors independently evaluated the search results according to the inclusion and exclusion criteria. There were no studies identified for inclusion and therefore no data extraction was completed. MAIN RESULTS: No RCTs were eligible for inclusion in this review. We report details of excluded prospective studies in an additional table and try to provide some useful evidence regarding current practice. AUTHORS' CONCLUSIONS: There were no RCTs eligible for inclusion in this review. In current practice the most common regimen for adult patients with thymic carcinoma or advanced thymoma is cisplatin-based chemotherapy. Considering the condition is rare, it is suggested that an international group is set up to organise and evaluate prospective collection of data from cohorts of patients to inform current clinical practice.